Therefore, SGLT-2 inhibitors appear to prevent the progression of AF and its tachyarrhythmic burden through improved insulin sensitivity and specific effects on myocardial metabolism, particularly under advanced glycation end products-overload and diabetic conditions [76]. The gene discussed is SLC5A2; the disease is atrial fibrillation.